|
Female gender, n (%)
|
70 (50.4%)
|
|
Age (yrs), mean ± SD
|
67.2 ± 15.9
|
|
Comorbid conditions, n (%)
|
131 (94.2%)
|
|
Diabetes mellitus
|
53 (38.1%)
|
|
Cardiovascular diseases
|
41 (29.5%)
|
|
Renal diseases
|
37 (26.6%)
|
|
Cerebrovascular diseases
|
35 (25.2%)
|
|
Solid malignancy
|
21 (15.1%)
|
|
Chronic pulmonary diseases
|
20 (14.3%)
|
|
Hematologic malignancy
|
16 (11.5%)
|
|
Liver diseases
|
10 (7.2%)
|
|
Organ transplantation
|
4 (2.9%)
|
|
HIV infection
|
2 (1.4%)
|
|
Previous hospitalization within 3 months, n (%)
|
73 (52.5%)
|
|
Site of infection in 139 patients at enrollment, n (%)
|
|
Lower respiratory tract infection
|
93 (66.9%)
|
|
Blood stream infection
|
40 (28.8%)
|
|
Urinary tract infection
|
18 (12.9%)
|
|
Gastrointestinal tract infection
|
11 (7.9%)
|
|
Skin and soft tissue infection
|
8 (5.8%)
|
|
Surgical site infection
|
1 (0.7%)
|
|
Bone and joint infection
|
1 (0.7%)
|
|
Documented bacteria-caused infections in 110 patients that required colistin therapy, n (%)
|
|
A. baumannii
|
79 (71.8%)
|
|
K. pneumoniae
|
18 (16.4%)
|
|
P. aeruginosa
|
9 (8.2%)
|
|
E. coli
|
2 (1.8%)
|
|
E. cloacae
|
2 (1.8%)
|
|
Medical procedure, n (%)
|
|
Mechanical ventilation
|
117 (84.2%)
|
|
Central venous catheterization
|
85 (61.2%)
|
|
Chronic intermittent hemodialysis
|
53 (38.1%)
|
|
Severity of patient illness, mean ± SD
|
|
APACHE II score at enrollment
|
21.8 ± 7.4
|
|
Antibiotic use for the current hospitalization prior to study enrollment, n (%)
|
134 (96.4%)
|
|
Carbapenems
|
112 (80.6%)
|
|
Cephalosporins
|
56 (40.3%)
|
|
Beta-lactam/beta-lactamase inhibitors
|
75 (54.0%)
|
|
Fluoroquinolones
|
39 (28.1%)
|
|
Vancomycin
|
43 (30.9%)
|
|
Aminoglycosides
|
6 (4.3%)
|
|
Colistin
|
9 (6.8%)
|
|
Colistin use within 3 months prior to study enrollment, n (%)
|
15 (10.8%)
|
